Protalix Biotherapeutics Inc (PLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protalix Biotherapeutics Inc (PLX) has a cash flow conversion efficiency ratio of 0.042x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.03 Million) by net assets ($48.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PLX net asset quality score to measure how much of total assets are equity-financed.
Protalix Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Protalix Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Protalix Biotherapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Protalix Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protalix Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sensorion SA
PA:ALSEN
|
-0.332x |
|
Parsan Makina Parcalari Sanayi AS
IS:PARSN
|
0.002x |
|
Gurit Holding AG
SW:GURN
|
0.570x |
|
Solocal Group SA
PA:LOCAL
|
-0.613x |
|
Mikro MSC Bhd
KLSE:0112
|
0.019x |
|
Formuepleje Limittellus
CO:FPILIM
|
N/A |
|
Texmaco Infrastructure & Holdings Limited
NSE:TEXINFRA
|
0.139x |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
N/A |
Annual Cash Flow Conversion Efficiency for Protalix Biotherapeutics Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Protalix Biotherapeutics Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see PLX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $48.23 Million | $-11.99 Million | -0.249x | -223.88% |
| 2024-12-31 | $43.21 Million | $8.67 Million | 0.201x | +611.27% |
| 2023-12-31 | $33.57 Million | $-1.32 Million | -0.039x | -101.67% |
| 2022-12-31 | $-10.64 Million | $-25.00 Million | 2.350x | +37.89% |
| 2021-12-31 | $-6.04 Million | $-10.29 Million | 1.704x | +76.47% |
| 2020-12-31 | $-27.04 Million | $-26.11 Million | 0.966x | +250.76% |
| 2019-12-31 | $-70.32 Million | $-19.36 Million | 0.275x | +88.03% |
| 2018-12-31 | $-52.88 Million | $-7.74 Million | 0.146x | -54.16% |
| 2017-12-31 | $-31.29 Million | $-9.99 Million | 0.319x | -90.09% |
| 2016-12-31 | $-9.96 Million | $-32.10 Million | 3.224x | +244.34% |
| 2015-12-31 | $10.87 Million | $-24.28 Million | -2.233x | -524.10% |
| 2014-12-31 | $-55.60 Million | $-29.28 Million | 0.527x | -53.71% |
| 2013-12-31 | $-26.95 Million | $-30.65 Million | 1.138x | +701.39% |
| 2012-12-31 | $-3.36 Million | $635.00K | -0.189x | -120.93% |
| 2011-12-31 | $-26.08 Million | $-23.57 Million | 0.904x | -73.39% |
| 2010-12-31 | $-11.32 Million | $-38.46 Million | 3.397x | +21.38% |
| 2009-12-31 | $15.88 Million | $44.45 Million | 2.799x | +874.99% |
| 2008-12-31 | $44.35 Million | $-16.02 Million | -0.361x | -120.10% |
| 2007-12-31 | $63.69 Million | $-10.45 Million | -0.164x | +21.74% |
| 2006-12-31 | $24.28 Million | $-5.09 Million | -0.210x | -164.51% |
| 2005-12-31 | $914.43K | $-72.47K | -0.079x | +76.65% |
| 2004-12-31 | $495.36K | $-168.12K | -0.339x | -62.75% |
| 2003-12-31 | $655.43K | $-136.68K | -0.209x | -13.26% |
| 2002-12-31 | $796.15K | $-146.59K | -0.184x | +77.94% |
| 2001-12-31 | $945.91K | $-789.43K | -0.835x | -2011.77% |
| 2000-12-31 | $1.34 Million | $-53.11K | -0.040x | +95.54% |
| 1999-12-31 | $1.59 Million | $-1.41 Million | -0.886x | -226.92% |
| 1998-12-31 | $3.35 Million | $-909.52K | -0.271x | -- |
| 1997-12-31 | $0.00 | $-247.92K | x | -- |
| 1996-12-31 | $0.00 | $-40.57K | x | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more